Intercept Pharmaceuticals (ICPT) Rating Lowered to Hold at BidaskClub

BidaskClub cut shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a buy rating to a hold rating in a report published on Tuesday, BidAskClub reports.

Several other equities research analysts also recently weighed in on the stock. B. Riley set a $169.00 price target on shares of Intercept Pharmaceuticals and gave the company a buy rating in a research report on Friday, April 12th. Wedbush set a $251.00 price target on shares of Intercept Pharmaceuticals and gave the company a buy rating in a research report on Friday, April 12th. Wells Fargo & Co raised their price target on shares of Intercept Pharmaceuticals from $99.00 to $104.00 and gave the company a market perform rating in a research report on Friday, April 12th. UBS Group raised their price target on shares of Intercept Pharmaceuticals to $139.00 and gave the company a buy rating in a research report on Thursday, March 28th. Finally, Oppenheimer reissued a buy rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, March 19th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and sixteen have given a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $144.05.

Shares of ICPT opened at $91.70 on Tuesday. The company has a market cap of $2.74 billion, a P/E ratio of -8.44 and a beta of 1.63. The company has a quick ratio of 4.22, a current ratio of 4.22 and a debt-to-equity ratio of 19.41. Intercept Pharmaceuticals has a twelve month low of $64.50 and a twelve month high of $133.74.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($2.97) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.42) by ($0.55). The firm had revenue of $53.30 million for the quarter, compared to the consensus estimate of $52.53 million. Intercept Pharmaceuticals had a negative net margin of 172.39% and a negative return on equity of 592.58%. Intercept Pharmaceuticals’s revenue was up 41.4% on a year-over-year basis. During the same period last year, the business earned ($4.43) EPS. On average, sell-side analysts anticipate that Intercept Pharmaceuticals will post -9.13 EPS for the current fiscal year.

In other news, insider David Shapiro sold 2,000 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $95.00, for a total transaction of $190,000.00. Following the completion of the sale, the insider now owns 41,499 shares of the company’s stock, valued at approximately $3,942,405. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Srinivas Akkaraju sold 23,438 shares of the business’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $128.78, for a total transaction of $3,018,345.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,504 shares of company stock valued at $3,969,947. 4.90% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of the company. FMR LLC grew its position in shares of Intercept Pharmaceuticals by 0.3% during the 4th quarter. FMR LLC now owns 4,448,170 shares of the biopharmaceutical company’s stock valued at $448,331,000 after acquiring an additional 13,468 shares during the period. Vanguard Group Inc lifted its stake in shares of Intercept Pharmaceuticals by 2.8% during the 3rd quarter. Vanguard Group Inc now owns 1,952,931 shares of the biopharmaceutical company’s stock valued at $246,772,000 after buying an additional 54,038 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Intercept Pharmaceuticals by 2.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,952,931 shares of the biopharmaceutical company’s stock valued at $246,772,000 after buying an additional 54,038 shares in the last quarter. BB Biotech AG lifted its stake in shares of Intercept Pharmaceuticals by 5.5% during the 4th quarter. BB Biotech AG now owns 575,719 shares of the biopharmaceutical company’s stock valued at $58,027,000 after buying an additional 30,000 shares in the last quarter. Finally, Two Sigma Investments LP lifted its stake in shares of Intercept Pharmaceuticals by 38.5% during the 4th quarter. Two Sigma Investments LP now owns 310,187 shares of the biopharmaceutical company’s stock valued at $31,264,000 after buying an additional 86,171 shares in the last quarter. 70.24% of the stock is owned by hedge funds and other institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Story: Asset Allocation Models, Which is Right For You?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.